Impact on follow-up strategies in patients with primary sclerosing cholangitis
Bergquist, Annika; Weismüller, Tobias J.; Levy, Cynthia; Rupp, Christian; Joshi, Deepak; Nayagam, Jeremy Shanika; Montano-Loza, Aldo J.; Lytvyak, Ellina; Wunsch, Ewa; Milkiewicz, Piotr; Zenouzi, Roman; Schramm, Christoph; Cazzagon, Nora; Floreani, Annarosa; Liby, Ingalill Friis; Wiestler, Miriam; Wedemeyer, Heiner; Zhou, Taotao; Strassburg, Christian P.; Rigopoulou, Eirini; Dalekos, George; Narasimman, Manasa; Verhelst, Xavier; Degroote, Helena; Vesterhus, Mette Nåmdal; Kremer, Andreas E.; Bündgens, Bennet; Rorsman, Fredrik; Nilsson, Emma; Jørgensen, Kristin Kaasen; von Seth, Erik; Cornillet Jeannin, Martin; Nyhlin, Nils; Martin, Harry; Kechagias, Stergios; Wiencke, Kristine; Werner, Mårten; Beretta-Piccoli, Benedetta Terziroli; Marzioni, Marco; Isoniemi, Helena; Arola, Johanna; Wefer, Agnes; Söderling, Jonas; Färkkilä, Martti; Lenzen, Henrike
Journal article, Peer reviewed
MetadataShow full item record
Original versionLiver international. 2022. 10.1111/liv.15286
Background & Aims: Evidence for the benefit of scheduled imaging for early detection of hepatobiliary malignancies in primary sclerosing cholangitis (PSC) is limited. We aimed to compare different follow-up strategies in PSC with the hypothesis that regular imaging improves survival. Methods: We collected retrospective data from 2975 PSC patients from 27 centres. Patients were followed from the start of scheduled imaging or in case of clinical follow-up from 1 January 2000, until death or last clinical follow-up alive. The primary endpoint was all-cause mortality. Results: A broad variety of different follow-up strategies were reported. All except one centre used regular imaging, ultrasound (US) and/or magnetic resonance imaging (MRI). Two centres used scheduled endoscopic retrograde cholangiopancreatography (ERCP) in addition to imaging for surveillance purposes. The overall HR (CI95%) for death, adjusted for sex, age and start year of follow-up, was 0.61 (0.47–0.80) for scheduled imaging with and without ERCP; 0.64 (0.48–0.86) for US/MRI and 0.53 (0.37–0.75) for follow-up strategies including scheduled ERCP. The lower risk of death remained for scheduled imaging with and without ERCP after adjustment for cholangiocarcinoma (CCA) or high-grade dysplasia as a time-dependent covariate, HR 0.57 (0.44–0.75). Hepatobiliary malignancy was diagnosed in 175 (5.9%) of the patients at 7.9 years of follow-up. Asymptomatic patients (25%) with CCA had better survival if scheduled imaging had been performed. Conclusions: Follow-up strategies vary considerably across centres. Scheduled imaging was associated with improved survival. Multiple factors may contribute to this result including early tumour detection and increased endoscopic treatment of asymptomatic benign biliary strictures.